UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/501,029	07/25/2005	Zita Jegesne Csakai	CytRx/016	3625

1473 7590 09/06/2007

ROPES & GRAY LLP
PATENT DOCKETING 39/361
1211 AVENUE OF THE AMERICAS
NEW YORK, NY 10036-8704

EXAMINER	
HABTE, KAHSAY	

ART UNIT	PAPER NUMBER
1624	

MAIL DATE	DELIVERY MODE
09/06/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/501,029	CSAKAI ET AL.	
	Examiner	Art Unit	
	Kahsay Habte	1624	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *30 July 2007*.

2a)☒ This action is **FINAL**. 2b)☐ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *21,27-32 and 35-37* is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☒ Claim(s) *21,27-32 and 35* is/are allowed.

6)☒ Claim(s) *36 and 37* is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☒ All b)☐ Some * c)☐ None of:

1.☒ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☒ Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date *8/23/2007*.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____.
5) ☐ Notice of Informal Patent Application
6) ☐ Other: _____.

DETAILED ACTION

1. Claims 21, 27-32 and 35-37 are pending in this application.

Response to Amendment

2. Applicant's amendment filed 07/30/2007 in response to the previous Office Action (03/29/2007) is acknowledged. Rejection of claims 35 and 36 U.S.C. § 112, second paragraph (items 5a-5b) has been obviated. The enablement rejection (item 4) has been maintained.

Claim Rejections - 35 USC § 112

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

> The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 36-37 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. In claim 36, it is recited a method for the treatment of vascular disease or diseases in general and in claim 37, it is recited a method of relaxation of blood vessels in general, but the specification is not enabled for such a scope.

In evaluating the enablement question, several factors are to be considered. Note *In re Wands*, 8 USPQ2d 1400 and *Ex parte Forman*, 230 USPQ 546. The factors include: 1) The nature of the invention, 2) the state of the prior art, 3) the predictability or lack thereof in the art, 4) the amount of direction or guidance present, 5) the presence or absence of working examples, 6) the breadth of the claims, and 7) the quantity of experimentation needed.

The scope of the claims is not adequately enabled solely based on the vaso-relaxing effect activity provided in the specification. First, the instant claims cover 'diseases' that are known to exist and those that may be discovered in the future, for which there is no enablement provided. The use disclosed in the specification is as pharmaceutical effective hydroxylamine derivatives, which are useful in the treatment of vascular diseases. Test procedures and assays are provided in the specification at pages 8-13 only for 6 compounds and it is concluded that the test compounds improved the relaxation properties significantly, which is the result of the functioning of the endothelium, due to the relative increase of the endothelium-related relation factors. However, there is nothing in the disclosure regarding how this *in vitro* data correlates to the treatment of the diverse disorders embraced the instant claims. The disorders encompassed by the instant claims (i.e. treatment of vascular diseases), some of which have been proven to be extremely difficult to treat. Vascular diseases are very broad in nature and differ one from the other significantly. Vascular disease is mainly caused by atherosclerosis (hardening of the arteries) due to a thickening of the lining of the arteries. The arteries are blood vessels that supply blood, oxygen and nutrients, to the

body from the heart. Atherosclerosis is a condition leading to narrow, hardened arteries so that there is insufficient blood flow to satisfy the needs of the tissue in question. Those parts of the body most affected by this disease suffer the consequences of an inadequate blood supply, namely poor function, tissue damage or death. There are different symptoms depending on where in the body the vascular disease occurs. It most commonly affects the arteries of the heart, brain and legs.

The heart - cardiovascular disease

When the heart is affected, heavy, tight central chest pain with exertion (angina) or breathing difficulties may be experienced. In the most serious cases, a coronary artery can become blocked by a blood clot (thrombosis) causing severe pain and a serious threat to life.

Cardiovascular disorders embrace a vast array of problems, many of which are contradictory to others. Thus, it covers hypertension and hypotension. It covers various types of arrhythmias; angina pectoris; the thrombotic symptoms of diabetes, atherosclerosis and hyperlipoproteinaemias; ischaemic heart disease including congestive heart failure and myocardial infarction; stroke, and peripheral vascular disorders, such as deep-vein thrombosis and thrombophlebitis percutaneous transluminal coronary angiography (PTCA); elevated blood levels of triglycerides, of total cholesterol or of LDL cholesterol; arteriosclerosis, peripheral vascular disease, cerebral vascular disease and pulmonary hypertension, migraine, cardiomyopathy, etc.

Not one compound --- let alone a genus of trillions of compounds, could possibly be effective against such disorders generally.

The brain - cerebrovascular disease

Atherosclerosis in the arteries of the brain can lead to strokes (CVAs) that cause paralysis or loss of other function, such as speech.

The legs - peripheral vascular disease

In the legs, atherosclerosis may cause cramping pain in the muscles on exertion (intermittent claudication).

In regard to the relaxation of blood vessels in general, the specification is not enabled for such a scope. Blood vessel is a vessel in the human or animal body in which blood circulates. The vessels that carry blood away from the heart are called **arteries**, and their very small branches are **arterioles**. Very small branches that collect the blood from the various organs and parts are called **venules**, and they unite to form **veins**, which return the blood to the heart. **Capillaries** are minute, thin-walled vessels that connect the arterioles and venules; it is through the capillaries that nutrients and wastes are exchanged between the blood and body tissues.

There is no reasonable basis for assuming that the myriad of compounds embraced by the claims will all share the same physiological properties since they are so structurally

dissimilar as to be chemically non-equivalent and there is no basis in the prior art for assuming the same. Note *In re Surrey*, 151 USPQ 724 regarding sufficiency of disclosure for a Markush group.

Thus, factors such as "sufficient working examples", "the level of skill in the art" and "predictability", etc. have been demonstrated to be sufficiently lacking in the use of the invention. In view of the breadth of the claim, the chemical nature of the invention, the unpredictability of ligand-receptor interactions in general, and the lack of working examples regarding the activity of the claimed compounds, one having ordinary skill in the art would have to undergo an undue amount of experimentation to use the invention commensurate in scope with the claims.

Response to arguments

4. Applicant's argument filed 07/30/2007 has been fully considered but it is not persuasive.

Applicants argue, "The scope of the claims is not defined by the cause of vascular disease, but the treatment, which has the effect of dilating the blood vessels". The examiner disagrees with applicant's argument. The rejection based on the fact that the treatment of vascular disease in general is very broad in nature (see above) and that it is not enabled. Applicant's specification is not enabled for the treatment of

vascular diseases in general. The reason that vascular diseases have different causes indicates that the treatment of one vascular disease is different one from the other. It is recommended that applicants delete claims 36 and 37 to overcome this rejection.

Allowable Subject Matter

5. Claims 21, 27-32 and 35 are allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Conclusion

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kahsay Habte, Ph. D. whose telephone number is (571) 272-0667. The examiner can normally be reached on M-F (9.00AM- 5:30PM).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached at (571) 272-0661. The fax phone number for the organization where this application or proceeding is assigned is (571)-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Kahsay Habte
Primary Examiner
Art Unit 1624

KH
September 4, 2007